SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as community members discuss potential partnerships, including speculation around Apple and TSMC, and the impact of government investment in domestic chip manufacturing. Bullish sentiment is fueled by the possibility of Intel becoming a key player in the U.S. semiconductor industry. Some traders are also discussing short positions and potential pullbacks after the recent price increase.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending, driven by community enthusiasm and meme-driven engagement centered around the classic "What's UpDog?" joke. Active community members are emphasizing its availability on the Jupiter Strict List and encouraging others to join the UpDog movement on the Solana network. The community highlights the project's longevity and locked liquidity as key strengths.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to positive Phase 2 trial data for its skin drug, sonelokimab, sparking buyout speculation and excitement among retail investors. The community is actively discussing the potential for larger gains and debating the market's reaction to the news, with some cautioning about a possible "sell the news" event. Trading halts and order rejections are also being noted.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is experiencing heightened interest, possibly due to its privacy features and upcoming halving event, with some community members drawing comparisons to Bitcoin's early days and anticipating significant price appreciation. Community discussions revolve around price targets and the potential for Zcash to outperform other cryptocurrencies. Zcash's focus on shielded transactions is also seen as a key differentiator in a world increasingly concerned about financial privacy.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending following the announcement of a significant private placement, with community members discussing key support and resistance levels to watch. Some traders are pointing to the potential for dilution due to warrants included in the deal. Others are optimistic about continued momentum given the tight float and recent after-hours spike.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as community members discuss Cigna adding Auvelity to its preferred drug list in 2026, potentially setting a precedent for other insurers. Sponsorship of educational events and analysis of prescription data are also fueling conversation. Despite some concerns regarding share sales and pipeline candidates, many remain optimistic about Axsome's growth trajectory and potential FDA approvals.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF ($GDX) is trending amid community discussion about a potential resource supercycle and breakouts in the resource sector. Some analysts suggest gold miners are undervalued and poised for further gains, while others point to technical indicators suggesting a short-term pullback may be due. Community members are also discussing the potential impact of geopolitical events and monetary policy on gold prices.

BJ's Wholesale Club Holdings, Inc. engages in the operation of membership warehouse clubs. Its product categories include grocery, household and pet, television and electronics, furniture, computer and tablets, patio and outdoor living, lawn and garden, baby and kids, toys, home, health and beauty, appliances, and jewelry. The company was founded in 1984 and is headquartered in Marlborough, MA.

BJ`s Wholesale Club Holdings Inc

BJ's Wholesale Club is trending as investors discuss its revenue and membership growth, along with plans to open new stores and potential share buybacks. The community is weighing the impact of digital transformation, potential mergers, and target price adjustments from analysts. Sympathy dips with competitors like Costco and potential buying opportunities are also being actively considered.

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.

Dermata Therapeutics Inc

Dermata Therapeutics is trending due to anticipation surrounding upcoming Phase 3 trial results for its acne treatment, XYNGARI, with the community actively discussing the company's low float and potential for a significant price increase. Community members highlight the potential for a short squeeze and are closely monitoring the stock's accumulation patterns, while also pointing to the company's cash position and recent patent news as potential catalysts. Overall, the conversation is centered on the expectation of positive news and the possibility of a substantial upward movement.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

NOC is trending due to a potential contract win and increased defense spending, sparking community interest in call options. Discussions highlight bullish setups, strategic partnerships, and the stock's alignment with rising geopolitical tensions. Community members are closely monitoring developments in the aerospace and defense sector, with some anticipating a shift towards more advanced military systems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Scholar Rock (SRRK) rose about 2% on Tuesday morning after falling 12% in the pre-market session after the U.S. Food and Drug Administration refused to approve its Apitegromab drug for the treatment of patients with spinal muscular atrophy (SMA).The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.scholarrock.com/news-releases/news-release-details/fda-issues-complete-response-letter-crl-apitegromab-treatment">stated</a> that the FDA raised concerns identified during a routine general site inspection of Catalent Indiana LLC, a third-party fill-finish facility. The agency did not make any observations specific to its drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data, the company said.Catalent Indiana was acquired by Danish drugmaker Novo Nordisk (NVO) in December. The facility submitted a response in early August 2025 to address the observations noted by the FDA and has continued to take corrective actions, the company said.Scholar Rock said it will resubmit its application for Apitegromab once Catalent Indiana’s issues with the FDA are resolved. The company stated that it believes the FDA will be able to act expeditiously on the application once the manufacturing issues have been resolved. “We are continuing to work closely with Catalent Indiana on the FDA’s manufacturing observations so that we can resubmit the apitegromab BLA (application) as soon as possible,” said CEO David L Hallal.Scholar Rock has also submitted Apitegromab for approval by the European Medicines Agency, and a decision is anticipated near mid-2026, the company said. It expects a European launch for the drug in the second half of 2026, starting with Germany.Scholar Rock believes Apitegromab may lead to a clinically meaningful improvement in motor function in patients with Spinal Muscular Atrophy (SMA), a rare, severe, genetic neuromuscular disease characterized by motor function decline.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_9_42_28_AM_png_308ee0f990.webp" alt="SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>Scholar Rock is not the only company whose submissions have been delayed or denied following the FDA’s site inspection at Catalent's Indiana facility. Last month, Regeneron (REGN) <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">announced</a> that the FDA had extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions due to issues identified at the facility. &nbsp;SRRK stock is down 23% this year but up approximately 282% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amneal-pharma-stock-rises-on-fda-approval-for-generic-version-of-abbvie-eyedrops/chDhHHIR35Q">Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Scholar Rock Holding logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues

The company stated that the FDA did not make any observations specific to the drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data. 

Equity

The company stated that the FDA did not make any observations specific to the drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data. 


Veru Announces Novel Modified-Release Oral Formulation for Enobosarm 

VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.

Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, in combination with Tirzepatide, helped preserve lean mass during Tirzepatide-induced weight loss in a mid-stage study.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-positive-phase-2-embraze-trial-results">trial</a> demonstrated that 30% of the total weight loss with Tirzepatide alone was due to lean mass loss. Tirzepatide is the active ingredient in Eli Lilly's weight loss therapy Zepbound.Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.Reduction in body weight, however, was marginally higher in patients who received Tirzepatide alone.No subjects experienced serious adverse events or discontinuations considered to be related to apitegromab treatment, and there were no deaths, the company added.Akshay Vaishnaw, President of R&amp;D, Scholar Rock, said that while therapies like Tirzepatide have been an effective innovation for people with obesity, they result in substantial loss of lean muscle mass for patients, leading to unwanted health risks.Vaishnaw added that the company is focused on preparing for the launch of Apitegromab and, following its potential approval for spinal muscular atrophy, looks forward to studying it in a range of neuromuscular diseases with high unmet needs.Approval for Apitegromab in spinal muscular atrophy is expected by late September.Scholar Rock is not alone in attempting to preserve lean mass during drug-induced weight loss. Earlier this month, Regeneron (REGN) said that a mid-stage trial demonstrated that approximately 35% of Semaglutide-induced weight loss was due to loss of lean mass. However, combining Semaglutide, the active ingredient in Novo Nordisk’s weight loss drug Wegovy, with Regeneron’s Trevogrumab with or without Garetosmab helped preserve lean mass while increasing loss of fat mass, the company said.On Stocktwits, retail sentiment around Scholar Rock jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_1_49_41_PM_png_73aabfb93c.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:50 p.m. ET on June 18, 2025 | Source: Stocktwits" width="627" height="66"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:50 p.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, noted that the lack of increased weight loss with the combination compared to Tirzepatide alone is bearish.<stembedurl>https://stocktwits.com/BioLong123/message/618251994</stembedurl><a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> is down by 18% this year but up by over 320% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/coinbase-circle-pop-as-stablecoin-legislation-clears-senate/chlsfGnRR2K">Coinbase, Circle Pop As Stablecoin Legislation Clears Senate – But These Two Stocks Took A Hit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss

Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.

Shares of Akero Therapeutics, Inc. (AKRO) jumped 3% on Friday afternoon after Jefferies said the company has a “promising” takeover potential.Jefferies thinks big pharma companies are "still on the hunt" for deals as Pfizer (PFE), Biogen (BIIB), Merck (MRK), Eli Lilly (LLY), Gilead (GILD), and others have publicly discussed active business development to "fill voids."Jefferies named South San Francisco-based Akero among the names it believes hold promise, alongside Scholar Rock (SRRK).The firm noted that Akero has potential sales of $2 billion to $3 billion and "clean and strong" Phase II data of its lead product candidate, Efruxifermin, in patients with non-alcoholic Steatohepatitis.As for Scholar Rock (SRRK), Jefferies deems it a promising target with likely approval for its investigational treatment Apitegromab in spinal muscular atrophy by late September.The company’s upcoming mid-stage trial data of Apitegromab in obesity "could be a clearing event" that could help simplify the stock's valuation, it added.On Stocktwits, retail sentiment around Akero stayed within ‘bearish’ territory over the past 24 hours, coupled with ‘low’ message volume.<figure class="image"><img style="aspect-ratio:625/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_1_36_24_PM_png_6b185bcea0.webp" alt="AKRO's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="625" height="66"><figcaption>AKRO's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure>According to data from Koyfin, all 11 analysts covering AKRO rate it a ‘Buy’ or higher. The stock has an average price target of $76.30.Meanwhile, retail sentiment around SRRK stayed ‘bearish’ over the last 24 hours while message volume took a dip from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:633/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_1_37_19_PM_png_cb246dfd4a.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="633" height="65"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure> All of the 10 analysts covering SRRK also rate it ‘Buy’ or higher, with an average price target of $49.67.While <a href="https://stocktwits.com/symbol/AKRO">AKRO</a> has nearly doubled its value this year, <a href="https://stocktwits.com/symbol/SRRK">SRRK</a> is down by over 25%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/merck-gets-fda-approval-for-keytruda-in-more-head-and-neck-cancer-patients/chliQJzRRbZ">Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mergers and Acquisitions message in neon lights. (Image Courtesy: Getty Images)

Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased

Jefferies thinks big pharma companies are "still on the hunt" for deals. 

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases...

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the Company), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious...

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Scholar Rock Holding Corp

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

SRRK
Scholar Rock Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SRRK News

SRRK Scholar Rock Holding Corp